open access

Vol 6, No 6 (2017)
CASE REPORT
Published online: 2018-01-26
Get Citation

Sitagliptin induced splenic infarcts

Raiz Ahmad Misgar, Javaid Ahmad Bhat, Arshad Iqbal Wani, Mir Iftikhar Bashir
DOI: 10.5603/DK.2017.0035
·
Clinical Diabetology 2017;6(6):215-217.

open access

Vol 6, No 6 (2017)
CASE REPORT
Published online: 2018-01-26

Abstract

  Sitagliptin belongs to the class of dipeptidyl pepti­dase-4 (DPP-4) inhibitors. DPP-4 inhibitors are remark­ably well tolerated oral antihyperglycemic drugs with an adverse effect profile similar to that of placebo. No adverse effects have been reported even with overdose of sitagliptin in suicide attempts. We present here case summary of a 35-year-old female with type 2 diabetes mellitus and major depressive disorder who presented with multiple splenic infarcts after ingestion of sitag­liptin 700 mg and metformin 14 g with suicidal intent. To the best of our knowledge, there are no published reports of splenic infarcts as an adverse event of sit­agliptin. (Clin Diabetol 2017; 6, 6: 215–217)

Abstract

  Sitagliptin belongs to the class of dipeptidyl pepti­dase-4 (DPP-4) inhibitors. DPP-4 inhibitors are remark­ably well tolerated oral antihyperglycemic drugs with an adverse effect profile similar to that of placebo. No adverse effects have been reported even with overdose of sitagliptin in suicide attempts. We present here case summary of a 35-year-old female with type 2 diabetes mellitus and major depressive disorder who presented with multiple splenic infarcts after ingestion of sitag­liptin 700 mg and metformin 14 g with suicidal intent. To the best of our knowledge, there are no published reports of splenic infarcts as an adverse event of sit­agliptin. (Clin Diabetol 2017; 6, 6: 215–217)

Get Citation

Keywords

dipeptidyl peptidase-4 inhibitors, sitagliptin, splenic infarcts

About this article
Title

Sitagliptin induced splenic infarcts

Journal

Clinical Diabetology

Issue

Vol 6, No 6 (2017)

Pages

215-217

Published online

2018-01-26

DOI

10.5603/DK.2017.0035

Bibliographic record

Clinical Diabetology 2017;6(6):215-217.

Keywords

dipeptidyl peptidase-4 inhibitors
sitagliptin
splenic infarcts

Authors

Raiz Ahmad Misgar
Javaid Ahmad Bhat
Arshad Iqbal Wani
Mir Iftikhar Bashir

References (10)
  1. Deacon CF, Lebovitz HE, Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011; 13(1): 7–18.
  2. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014; 114(11): 1788–1803.
  3. Furukawa S, Kumagi T, Miyake T, et al. Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature. Endocr J. 2012; 59(4): 329–333.
  4. Sehra S, Jaggi S, Sehra D, et al. Management of Sitagliptin and Metformin Combination Toxic Overdose. J Assoc Physicians India. 2016; 64(11): 80–81.
  5. Januvia and Splenic infarction- from FDA reports. http://www.ehealthme.com/ds/januvia/splenic-infarction/;25th July 2017 (30th July 2017).
  6. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond). 2005; 108(4): 277–292.
  7. Koyama T, Gao M, Ueda T, et al. Different enzyme activities in coronary capillary endothelial cells. Adv Exp Med Biol. 1997; 411: 359–364.
  8. Heymann E, Mentlein R. A negative blood-clotting factor lining the vessels. Naturwissenschaften. 1982; 69(4): 189–191.
  9. Mentlein R, Heymann E. Dipeptidyl peptidase IV inhibits the polymerization of fibrin monomers. Arch Biochem Biophys. 1982; 217(2): 748–750.
  10. Krijnen PAJ, Hahn NE, Kholová I, et al. Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients. Basic Res Cardiol. 2012; 107(1): 233.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl